Circulating cell-free DNA in the peripheral blood plasma of patients is an informative biomarker for multiple myeloma relapse
Author:
Funder
Celgene
Japanese Society of Hematology
Publisher
Springer Science and Business Media LLC
Subject
Oncology,Hematology,General Medicine,Surgery
Link
https://link.springer.com/content/pdf/10.1007/s10147-021-01991-z.pdf
Reference25 articles.
1. Kumar SK, Rajkumar V, Kyle RA et al (2017) Multiple myeloma. Nat Rev Dis Primers 3:17046. https://doi.org/10.1038/nrdp.2017.46
2. Kumar SK, Rajkumar SV, Dispenzieri A et al (2008) Improved survival in multiple myeloma and the impact of novel therapies. Blood 111(5):2516–2520. https://doi.org/10.1182/blood-2007-10-116129
3. Imai Y, Hirano M, Kobayashi M et al (2019) HDAC inhibitors exert anti-myeloma effects through multiple modes of action. Cancers (Basel). https://doi.org/10.3390/cancers11040475
4. Gulla A, Anderson KC (2020) Multiple myeloma: the (r)evolution of current therapy and a glance into future. Haematologica. https://doi.org/10.3324/haematol.2020.247015
5. Yasui H, Ishida T, Maruyama R et al (2012) Model of translational cancer research in multiple myeloma. Cancer Sci 103(11):1907–1912. https://doi.org/10.1111/j.1349-7006.2012.02384.x
Cited by 10 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Bridging horizons beyond CIRCULATE-Japan: a new paradigm in molecular residual disease detection via whole genome sequencing-based circulating tumor DNA assay;International Journal of Clinical Oncology;2024-03-29
2. Sensitivity, specificity, and accuracy of molecular profiling on circulating cell-free DNA in refractory or relapsed multiple myeloma patients, results of MM-EP1 study;Leukemia & Lymphoma;2024-03-03
3. Liquid biopsy-based monitoring of residual disease in multiple myeloma by analysis of the rearranged immunoglobulin genes–A feasibility study;PLOS ONE;2023-05-26
4. Liquid biopsies and minimal residual disease in lymphoid malignancies;Frontiers in Oncology;2023-05-09
5. Multiple Myeloma in the Era of Novel Agents and Stem Cell Therapies;Recent Updates on Multiple Myeloma;2023-03-15
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3